Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Understanding the burden of orofacial involvement and patient treatment preferences in systemic sclerosis: results from a large international survey.

Arthritis care & research·2026

Same author

Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns.

Arthritis care & research·2026

Same author

Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratification.

Arthritis care & research·2026

Same author

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026

Same author

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Arthritis care & research·2026

Same author

Lips in health and in systemic sclerosis: relevant physiology, pathogenesis, existing therapeutic approaches and unmet needs.

Journal of scleroderma and related disorders·2026

Search research articles

Related Experiment Video

Updated: Sep 18, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Comorbidities' Effect on IPF: Pathogenesis and Management.

Andrea Salotti¹, Maria Chianese¹, Antonio Romallo¹

¹Pulmonology Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Hospital of Cattinara, 34149 Trieste, Italy.

|June 26, 2025

Summary

This summary is machine-generated.

Managing idiopathic pulmonary fibrosis (IPF) requires a dual approach. This review explores comorbidities like cardiovascular disease and GERD, emphasizing integrated care for better patient outcomes.

Keywords:

cardiovascular disease comorbidities gastroesophageal reflux disease idiopathic pulmonary fibrosis (IPF)lung cancer obstructive sleep apnea pulmonary hypertension

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Sep 18, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Area of Science:

Pulmonology
Internal Medicine
Medical Comorbidities

Background:

Idiopathic pulmonary fibrosis (IPF) management traditionally focuses on the disease itself.
Growing recognition of IPF's complexity necessitates addressing associated comorbidities.
Comorbidities significantly impact patient prognosis and quality of life in IPF.

Purpose of the Study:

To comprehensively review comorbidities associated with IPF.
To explore current and emerging management strategies for these comorbidities.
To highlight the importance of a holistic, individualized approach to IPF care.

Main Methods:

Narrative review of existing literature on IPF and its comorbidities.
Synthesis of research on cardiovascular disease, lung cancer, GERD, OSA, and mental health in IPF patients.
Analysis of current and novel therapeutic interventions.

Main Results:

IPF frequently co-occurs with conditions such as cardiovascular disease, lung cancer, GERD, and OSA.
Effective IPF management requires addressing these comorbidities concurrently.
Interdisciplinary collaboration is crucial for optimizing patient care.

Conclusions:

A dual approach targeting IPF and its comorbidities is essential for improving survival and quality of life.
Understanding the interplay between IPF and comorbidities allows for tailored treatment plans.
Further research and integrated care models are needed for comprehensive IPF management.